Post-market review of medicines for smoking cessation – stakeholder forum outcome

15 February 2021 - A stakeholder forum was held for the post-market review of medicines for smoking cessation via webinar on ...

Read more →

ICER publishes evidence report on roxadustat for treating anaemia in chronic kidney disease

28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient ...

Read more →

ICER publishes evidence report on therapies for high cholesterol

22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...

Read more →

ICER releases draft evidence report on therapies for lupus nephritis

22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...

Read more →

PBAC Public Summary Documents (rejections/deferrals/other matters) - September 2020 intracycle meeting

15 January 2021 - The Public Summary Documents (rejections/deferrals/other matters) from the September 2020 PBAC untracycle meeting are now available. ...

Read more →

Closure of the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis

21 December 2020 - A plain language summary for the post-market review of the use of biologics in the treatment ...

Read more →

Report on the collection of under co-payment data 2019-20

18 December 2020 - The report on the collection of under co-payment data 2019-20 is now available. ...

Read more →

FDA updates list of off-patent, off-exclusivity drugs without an approved generic

17 December 2020 - Today, the U.S. FDA published an update to the “List of Off-Patent, Off-Exclusivity Drugs without an Approved ...

Read more →

ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer

17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...

Read more →

PBS Expenditure and Prescriptions Report 2019-20

17 December 2020 - The PBS Expenditure and Prescriptions Report 1 July 2019 to 30 June 2020 is now available. ...

Read more →

IQWiG publishes 1,000th report

2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...

Read more →

ICER publishes final report and policy recommendations for haemophilia A therapies

20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...

Read more →

Drug Utilisation Sub-Committee outcome statement

17 November 2020 - The Outcome Statement from the October 2020 Drug Utilisation Sub-Committee meeting is now available. ...

Read more →

Public Summary Documents - PBAC July 2020 meeting

13 November 2020 - The Public Summary Documents (first time rejections and deferrals) from the July 2020 PBAC meeting are now ...

Read more →

Drug Utilisation Sub-Committee utilisation analysis public release documents

13 November 2020 - The utilisation analysis public release documents from the June 2020 Drug Utilisation Sub-Committee meeting are now ...

Read more →